Welcome to our dedicated page for Humacyte SEC filings (Ticker: HUMAW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Humacyte, Inc. (HUMAW) SEC filings page on Stock Titan provides access to the company’s public regulatory disclosures, with AI-powered summaries to help interpret complex documents. Humacyte is a biotechnology company focused on universally implantable bioengineered human tissues and organs, and its filings give detailed insight into its financing structure, warrant terms, and status as an emerging growth company.
Investors and researchers can review Humacyte’s current reports on Form 8-K, which describe material events such as amendments to its Revenue Interest Purchase Agreement. These filings outline repayment obligations, restricted cash requirements for the benefit of the financing agent, and the terms of an optional call feature that allows Humacyte to repurchase revenue interests at a defined repurchase price, with a portion potentially payable in common stock if specified conditions are met.
On this page, users can also track information related to Humacyte’s redeemable warrants listed on The Nasdaq Stock Market LLC under the symbol HUMAW, where each whole warrant is exercisable for one share of common stock at a stated exercise price. Stock Titan’s AI tools summarize key points from filings, highlight important sections, and clarify technical language, helping users understand how these documents relate to Humacyte’s capital structure and biological products business.
Filings are updated from the SEC’s EDGAR system, so new 8-Ks and other reportable documents appear as they are made public. This makes it easier to locate disclosures about financial obligations, warrant terms, and other regulatory information that shape the risk profile and corporate structure of Humacyte, Inc.
Humacyte, Inc. (HUMA) is now a commercial-stage biotech company after the FDA granted full approval on December 19, 2024 for Symvess, an acellular tissue engineered vessel (ATEV), for adult extremity arterial injury when urgent revascularization is needed and autologous vein is not feasible. U.S. commercial launch began in the first quarter of 2025.
The company’s platform grows bioengineered, decellularized human vessels at scale in its 83,000 sq. ft. facility using modular LUNA200 systems, with capacity to produce thousands of ATEVs annually in multiple diameters and lengths. As of December 31, 2025, ATEVs had been implanted in about 636 patients across vascular trauma, hemodialysis access and peripheral artery disease, plus expanded access and humanitarian use, with low infection rates, no clinical rejection and evidence of remodeling into living tissue.
Humacyte is pursuing additional indications, including AV access for hemodialysis (positive Phase 3 V007 results and an ongoing women-focused Phase 3 V012 with a planned supplemental BLA in the second half of 2026), PAD, CABG, pediatric heart surgery and a BioVascular Pancreas concept for Type 1 diabetes. Multiple RMAT designations and Department of Defense support underscore its regulatory and strategic positioning.
Fresenius Medical Care Holdings, Inc. and Fresenius Medical Care AG report their updated ownership in Humacyte, Inc. common stock. As of this amendment, Fresenius Medical Care Holdings, Inc. beneficially owns 18,312,735 shares, representing 8.4% of Humacyte’s outstanding voting shares.
The ownership percentage is calculated against 218,453,511 shares outstanding as of March 20, 2026, which include shares previously outstanding plus 5,725,190 shares issued on December 15, 2025 and 25,000,000 shares issued on March 20, 2026. The decrease from 9.5% to 8.4% results solely from these new issuances; Fresenius states it has neither acquired nor disposed of Humacyte shares since its initial 2021 report.
Humacyte, Inc. is raising $20 million through a registered direct offering of 25,000,000 shares of common stock at $0.80 per share. After placement fees and expenses, net proceeds are expected to be about $18.4 million.
The cash will support commercialization of Symvess in the vascular trauma indication, a planned Biologics License Application supplement for a hemodialysis use, related Phase 3 activities, broader pipeline development, and general corporate purposes. The offering, led by institutional investors, is expected to close on or about March 20, 2026, subject to customary conditions.
Humacyte, Inc. reported a material event on an Form 8-K documenting Amendment No. 2 to a Revenue Interest Purchase Agreement executed on September 17, 2025. The amendment names the parties as Humacyte Global, Inc., Humacyte, Inc. and the purchasers TPC Investments III LP, TPC Investment Solutions LP and Hook SA LLC.
The filing indicates the inclusion of the amendment as an exhibit and an Inline XBRL cover page file. No financial terms, changes to covenants, or quantitative impacts were disclosed in the provided text, so the filing primarily records the contractual amendment rather than operational results.